Earendil Labs key facts
- Developer of an artificial intelligence scientific computing platform intended for biotechnology firms, pharmaceutical companies, and research institutions.
- It has raised $787.0M; the latest was Later Stage VC ($787.0M) in Mar 2026.
- Notable investors include DST Global, INCE Capital, Dimension Capital Management, 21Vita, Harvest Miracle Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·Watch Earendil Labs: the Monday email on marks, rounds and moves
Earendil Labs funding rounds
No funding rounds for Earendil Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Earendil Labs investors
7 investors are on record for Earendil Labs, including DST Global, INCE Capital, Dimension Capital Management and 21Vita.
About Earendil Labs
Developer of an artificial intelligence scientific computing platform intended for biotechnology firms, pharmaceutical companies, and research institutions. The company develops an AI drug development platform and a high-throughput antibody engineering experiment platform, thereby enabling scientific teams to decode complex protein interactions and design innovative treatments.
- Sector
- Healthcare
- HQ
- Middletown, DE, United States
- Founded
- 2021
- Website
- earendil.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Earendil Labs doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.